Mohammed Abusafia

Mohammed Abusafia

Auto-generated profile, based on publicly available information

Mohammed Abusafia

Hypertrophic Cardiomyopathy Center, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J1-5, Cleveland Clinic , Cleveland, OH 44195

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MDMilind Y. Desai
Milind Y. Desai
AGAndrew Gaballa
Andrew Gaballa
YOYuichiro Okushi
Yuichiro Okushi
MAMohammed Abusafia
Mohammed Abusafia
SJShada Jadam
Shada Jadam
BXBo Xu
Bo Xu
Background: Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy treated at a multihospital referral center. Methods: We included 244 patients with obstructive hypertrophic cardiomyopathy (mean age, 64 years; 57% women, 21% with atrial fibrillation, 51% New York Heart Association class III, 82% on β‐blockers) treated with mavacamten for ≥3 months (171 for ≥12 months). Serial clinical and echocardiographic assessments were performed. Results: New York Heart Association class distribution improved over time: at 3 months 21% class I, 61% class II, and 18% class III; at 12 months 36% class I, 57% class II, and 8% class III. After a mean of 1.02 years, significant improvements were observed in resting and post‐Valsalva left ventricular outflow tract gradients (−31±33 and −57±46 mm Hg), interventricular septal thickness (−1.7±4 mm), left ventricular mass index (−9.5±32 g/m 2 ), left atrial volume index (−12±13 mL/m 2 ), E/e′ (−5.5±6.4), left ventricular global longitudinal strain (1.04%±3.1%), and various left atrial and right ventricular strain measures (all P <0.05). Temporary interruption occurred in 8 patients (3.2%), and 3 (1.2%) discontinued mavacamten permanently. There were 2 noncardiac deaths, 7 heart failure admissions, 14 cases of new‐onset atrial fibrillation, and 1 patient required septal reduction therapy. At the last visit, most patients were on 5 mg (49%) or 10 mg (26%) mavacamten. Conclusions: In this real‐world cohort, mavacamten treatment was associated with sustained symptomatic and echocardiographic improvements, suggesting a favorable disease‐modifying impact with minimal need for septal reduction therapy.

16 December 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MAMohammed Abusafia
Mohammed Abusafia
SJShada Jadam
Shada Jadam
VKVidyasagar Kalahasti
Vidyasagar Kalahasti
LDLifu Deng
Lifu Deng
SOSusan Ospina
Susan Ospina
MDMilind Y. Desai
Milind Y. Desai
Background: Thoracic ascending aortopathy (AA) is often asymptomatic and incidentally diagnosed, with surgical replacement recommended once it becomes aneurysmal. We report sex‐based characteristics and long‐term outcomes of patients with AA. Methods: This study analyzed 14 244 patients (21.1% women) with unrepaired AA (≥4 cm) diagnosed via echocardiography from 2010 to 2023, excluding those with acute aortic dissection/rupture at presentation (n=1179). Baseline data, including height‐indexed measurements (ascending aortic area height index and cross‐sectional area to height ratio), were collected. AA surgery and rates of aortic dissection/rupture during follow‐up were recorded. Cox proportional hazards and Kaplan–Meier survival analysis were performed for all‐cause mortality. Results: Women were older (63.6 versus 62.3 years) and had fewer comorbidities, including hypertension, diabetes, coronary artery disease, and dyslipidemia (all P <0.001). However, women had higher height‐indexed aortic measurements (ascending aortic area height index: 2.81 versus 2.59 cm/m; cross‐sectional area to height ratio: 10.3 versus 9.5 cm 2 /m, both P <0.001) and fewer aneurysms ≥5 cm (20.6% versus 22.8%, P =0.04). At 0.86 years, 26.1% underwent surgery, with higher rates in women (28.2% versus 25.6%, P =0.002) and low in‐hospital mortality (0.9%). Over 6.2 years, women had worse survival (14.2% versus 11.2%, log‐rank P <0.001), with female sex independently associated with higher mortality (hazard ratio [HR], 1.14; P <0.001). Aortic surgery improved survival (HR, 0.81; P <0.001). Among unoperated patients (n=10 523), 62.9% of deaths and 72.4% of dissections/ruptures occurred in women with aortic diameters <5 cm. Conclusions: Despite fewer comorbidities and higher surgical rates, women with AA had worse long‐term survival. Sex‐specific thresholds for AA surgery may warrant consideration.

21 September 2026 in The American Journal of Cardiology
Verified
Journal Article
Open access
SSStuti Shah
Stuti Shah
MAMohammed Abusafia
Mohammed Abusafia
HSHesham Sheashaa
Hesham Sheashaa
SJShada Jadam
Shada Jadam
SOSusan Ospina
Susan Ospina
MDMilind Y. Desai
Milind Y. Desai

31 August 2026 in Cardiovascular Research
Verified
Journal Article
Closed access
SKSusan K Keen
Susan K Keen
SSStuti Shah
Stuti Shah
HSHesham Sheashaa
Hesham Sheashaa
MAMohammed Abusafia
Mohammed Abusafia
SJShada Jadam
Shada Jadam
MDMilind Y Desai
Milind Y Desai
Aims: Extensive late gadolinium enhancement (LGE) is recognized in contemporary hypertrophic cardiomyopathy (HCM) risk assessment, but the prognostic value of lower quantitative thresholds remains debated. We aimed to evaluate whether quantitative LGE provides independent and incremental prognostic information beyond established clinical and phenotypic risk markers. Methods and results: This large contemporary cohort included 3035 patients (median age 58 years, 57% men); 56% had LGE, including 242 (8%) with LGE > 10%. Most patients have obstructive hypertrophic cardiomyopathy (71%), 1498 (69%) of which subsequently underwent septal reduction therapy at a median of 43 days [interquartile range (IQR) 5–107) from the cardiac magnetic resonance (CMR) date (1485 myectomies and 13 alcohol septal ablations). Over a median of 8.8 years, 331 (11%) primary endpoints occurred [295 cardiovascular deaths (9.7%) and 36 appropriate implantable cardioverter–defibrillator discharges (1.3%)]. On multivariable Cox proportional hazards analysis [adjusted for standard clinical and CMR variables, higher %LGE (1.05 per 1% increase, 95% confidence interval 1.03–1.06; P < 0.001)] was associated with primary events. Compared with no LGE, LGE ≥10% was associated with higher risk of the composite endpoint. Conclusion: In this large contemporary HCM cohort, quantitative LGE was independently associated with long-term adverse outcomes. LGE ≥10% identified patients at significantly higher risk, and incorporation of LGE improved discrimination beyond ESC and AHA/ACC risk assessment.